| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.11. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10. | IceCure Medical: IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation | 515 | PR Newswire | First patient enrolled and treated at West Cancer Center in Tennessee, USA CAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company")... ► Artikel lesen | |
| 20.10. | IceCure Medical: IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites | 409 | PR Newswire | CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive... ► Artikel lesen | |
| 13.10. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.10. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| 18.09. | Full Transcript: Icecure Medical Q2 2026 Earnings Call | 3 | Benzinga.com | ||
| 11.09. | IceCure Secures China NMPA Approval for ProSense Cryoablation System | 1 | Zacks | ||
| 10.09. | IceCure Medical wins China approval for ProSense cryoablation system | 2 | Seeking Alpha | ||
| 10.09. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.08. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.08. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.08. | IceCure Medical GAAP EPS of -$3.17 misses by $1.65, revenue of $1.82M beats by $0.37M | 3 | Seeking Alpha | ||
| 12.08. | IceCure Medical: IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year | 287 | PR Newswire | The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following... ► Artikel lesen | |
| 06.08. | IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment | 226 | PR Newswire |
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval
The site will... ► Artikel lesen | |
| 26.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.06. | What's Going On With IceCure Medical Stock On Friday? | 6 | Benzinga.com | ||
| 25.06. | IceCure Medical: IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | 218 | PR Newswire | CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive... ► Artikel lesen | |
| 18.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.06. | IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance | 566 | PR Newswire | Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated... ► Artikel lesen | |
| 02.06. | IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance | 1 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,800 | -1,50 % | Eckert&Ziegler vor dem Quartalsbericht: Kann der Schwung anhalten? | ||
| LANTHEUS | 90,40 | +0,44 % | Lantheus Holdings, Inc. - 10-Q, Quarterly Report | ||
| FRESENIUS | 52,48 | +1,18 % | Fresenius-Aktie +3%: Hält der Ausbruch über 48,48 €? | Die Fresenius-Aktie steht am Montag an der Spitze des Dax. Der Kurs des Medizinkonzerns und Krankenhausbetreibers zog am Vormittag um bis zu 3% an und erreichte bei 49,24 € ein Hoch seit Anfang März.... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,660 | +0,22 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,230 | -0,21 % | Fresenius Medical Care AG: Q3-EBIT unter Druck durch steigende Transformationskosten; weiterhin KAUFEN | Fresenius Medical Care (FME) meldete für das dritte Quartal 2026 ein Umsatzwachstum von 1,1% gegenüber dem Vorjahr auf EUR 4,94 Mrd., während das berichtete EBIT aufgrund erheblicher Restrukturierungsaufwendungen... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 3,610 | -0,28 % | Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027 | ||
| PRIVIA HEALTH GROUP | 24,420 | 0,00 % | Privia Health Group, Inc. - 10-Q, Quarterly Report | ||
| BRIGHTSPRING HEALTH SERVICES | 67,13 | -0,03 % | Guggenheim raises BrightSpring Health stock price target on growth | ||
| BILLIONTOONE | 114,01 | +0,06 % | BTIG reiterates Buy on BillionToOne stock, keeps $130 target | ||
| LIFESTANCE HEALTH GROUP | 13,770 | 0,00 % | BMO raises Lifestance Health stock price target on strong results | ||
| GENEDX | 62,28 | -0,14 % | GeneDx partners with Mirum for free genetic testing program | ||
| PROGYNY | 34,870 | +0,09 % | Progyny, Inc. - 10-Q, Quarterly Report | ||
| HEARTFLOW | 52,39 | 0,00 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 34,960 | -2,35 % | EQS-AFR: Carl Zeiss Meditec AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Carl Zeiss Meditec AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Carl Zeiss Meditec AG: Vorabbekanntmachung... ► Artikel lesen | |
| GERRESHEIMER | 31,200 | -0,38 % | JPMORGAN stuft GERRESHEIMER AG auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Gerresheimer mit einem Kursziel von 46 Euro auf "Overweight" belassen. Die Bestätigung der Jahresziele mache eine deutliche... ► Artikel lesen |